Where are we?

I must admit the lack of gusto by immutep on it's much vaunted name change has
disappointed me mildy....That aside, remember back with CVAC, may 19 2015,
phase 2 results came out and everything went berserk when in reality those that
followed cvac's progress new that it was gonna be good because we simply new
no deaths had been been reported so it worked to that point.....Anyway my wonderment
quickly went away when a correction occurred, yes, and I didn't take advantage of the
price surge....Anyway we will soon be approaching initial ph2 aipac news, I believe midyear..
GSK and Novartis are both approaching ph1 closures with Novartis already beginning ph2
in some disciplines midyear as well...EOC, Cytlimic are mystery's to me, very hard to research
and as Joe mentioned earlier, approval to progress clinical trials in USA is under review....
In my mind AIPAC is our strongest potential assett and the most advanced, I couldn't imagine
IMM entering the US with a new trial involving it, I'm wondering whether an alliance with
Merck and keytruda may be in the offing.....Stalemate at the moment but in the back of
my mind the actions of May 19 2015 remind me of possibilities given the ability of the
market to launch into action.....